Jim Cramer's Top Takeaways: Ambarella, Zoe's Kitchen, Thermo Fisher Scientific, Cardinal Health

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

AMBA Chart
AMBA data by YCharts

Ambarella (AMBA) : Cramer said this mobile chip maker has entered the pantheon of cult stocks. What's a cult stock? It's one that trades purely on momentum and not by any traditional valuation metrics.

The stocks of Amazon.com (AMZN) , Netflix (NFLX) , Tesla Motors (TSLA) and most recently Shake Shack (SHAK) , are all enshrined in the cult stock hall of fame.

What makes Ambarella so special? For starters the stock is up over 100% for the year, Cramer noted. When the company last reported, revenue soared by 73%, allowing the company to trounce Wall Street estimates. Management also spoke positively about seemingly endless growth from body cameras, aerial drones, cameras in your car and even in your household doorbell.

But Cramer said it's difficult to recommend a stock that's already had such a huge run, even if its earnings may justify the price in a few years. Stocks that go straight up almost always end badly. Sometimes you just need to admit that you missed it, he concluded.

ZOES Chart
ZOES data by YCharts

Zoe's Kitchen (ZOES) : Cramer sat down with Kevin Miles, president and CEO at Zoe's, the Mediterranean restaurant chain that's seen its shares up 17% so far in 2015.

Miles said the key to Zoe's success is providing good food that resonates with customers, something they've been doing for the past 20 years. Zoe's offers a menu that's better for you and also very flavorful.

Miles also commented on his company's business intelligence efforts with partner Tableau (DATA) . He said they began exploring business intelligence in 2009 and now provide franchisees with data on sales, labor and the overall health of their brand, all of which help for better planning and execution around the country.

Cramer and Zoe's remains both a great concept and one that has excellent execution.

TMO Chart
TMO data by YCharts

Thermo Fisher Scientific (TMO) : In his second exclusive interview, Cramer once again sat down with Marc Casper, president and CEO of Thermo Fisher, the scientific equipment company and Action Alerts PLUS holding that has become the arms dealer to the life sciences industry, providing everything they need to get the job done. Shares of Thermo Fisher are up just 2% in 2015.

Casper said despite being a global company that derives 50% of its revenue overseas, his company is navigating the global currency landscape very well and still expect to see 4% to 6% revenue growth in 2015 even with the currency pressures.

Casper commented on recent weakness in Japan, noting the Japanese government was late in passing a budget, which put a crimp on spending. That momentum is now rebuilding, he added. Sales in China have also been strong as Thermo Fisher is perfectly aligned with the Chinese government's priorities of health and food safety.

Another key driver for Thermo Fisher is research and innovation. Casper said 20% of revenue stem from products introduced over the past four years and no one spends more than TMO does, $700 million annually on research and development. That's why his company can partner with the earliest-stage biotech company and be its largest supplier all the way through gaining FDA approval.

CAH Chart
CAH data by YCharts

Cardinal Health (CAH) : Last week, Cramer highlighted his favorite drugstore chains, but this week he's highlighting the wholesale drug distribution stocks starting with Cardinal Health.

Cardinal is now a $29 billion company that provides drugs and other medical and surgical supplies. It derives 87% of its revenue from the pharmaceutical side of its business, thanks to a joint venture with CVS Health (CVS) last year. The company is also bolstering its surgical supply business by buying Cordis, the division of Johnson & Johnson (JNJ) that makes cardiovascular supplies like stents, for $1.94 billion.

Cramer said Cardinal is not the cheapest of the bunch and is therefor not his favorite, but it remains a steal trading at just 17.9 times earnings.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in TMO.

More from Opinion

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook